Sound waves tested to supercharge cancer drug
NCT ID NCT03237572
Summary
This small, early-stage study tested whether using focused ultrasound on a tumor could help the immunotherapy drug pembrolizumab work better against metastatic breast cancer. The study aimed to see if the order of treatments mattered—giving the drug before or after the ultrasound. It was a pilot study that enrolled 13 participants but was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.